Article
Supporting Information Available: Experimental procedures
and characterization data for the synthesis of intermediate 34b
and compounds 30 through 58b. Characterization data for
compounds 3a-i. This material is available free of charge via
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 3 1259
(16) Ma, Q.; Jones, D.; Springer, T. A. The chemokine receptor CXCR4
is required for the retention of B lineage and granulocytic pre-
cursors within the bone marrow microenvironment. Immunity
1999, 10, 463–471.
(17) Liles, W. C.; Broxmeyer, H. E.; Rodger, E.; Wood, B.; Hubel, K.;
Cooper, S.; Hangoc, G.; Bridger, G. J.; Henson, G. W.; Calandra,
G.; Dale, C. D. Mobilization of hematopoietic progenitor cells in
healthy volunteers by AMD3100, a CXCR4 antagonist. Blood
2003, 102, 2728–2730.
References
(18) Broxmeyer, H. E.; Orschell, C. M.; Clapp, D. W.; Hangoc, G.;
Cooper, S.; Plett, P. A.; Liles, W. C.; Li, X.; Graham-Evans, B.;
Campbell, T. B.; Calandra, G.; Bridger, G.; Dale, D. C.; Srour,
E. F. Rapid mobilization of murine and human hematopoietic stem
and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp.
Med. 2005, 201, 1307–1318.
(19) Burroughs, L.; Mielcarek, M.; Little, M. T.; Bridger, G.;
Macfarland, R.; Fricker, S.; Labrecque, J.; Sandmaier, B. M.;
Storb, R. Durable engraftment of AMD3100-mobilized autolo-
gous and allogeneic peripheral-blood mononuclear cells in a canine
transplantation model. Blood 2005, 106, 4002–4008.
(20) Devine, S. M.; Vij, R.; Rettig, M.; Todt, L.; McGlauchlen, K.;
Fisher, N.; Devine, H.; Link, D. C.; Calandra, G.; Bridger, G.;
Westervelt, P.; DiPersio, J. F. Rapid mobilization of functional
donor hematopoietic cells without G-CSF using Plerixafor, an
antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112,
990–998.
(21) Martin, C.; Bridger, G. J.; Rankin, S. M. Structural analogues of
AMD3100 mobilise haematopoietic progenitor cells from bone
marrow in vivo according to their ability to inhibit CXCL12
binding to CXCR4 in vitro. Br. J. Haematol. 2006, 134, 326–329.
(22) DiPersio, J. F.; Stadtmauer, E. A.; Nademanee, A.; Micallef, I. N.
M.; Stiff, P. J.; Kaufman, J. L.; Maziarz, R. T.; Hosing, C.;
(1) Berger, E. A.; Murphy, P. M.; Farber, J. M. Chemokine receptors
as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
Annu. Rev. Immunol. 1999, 17, 657–700.
(2) Moore, J.; Doms, R. W. The entry of entry inhibitors: a fusion of
science and medicine. Proc. Natl. Acad. Sci. U.S.A. 2003, 100,
10598–10602.
(3) Wilkin, T. J.; Su, Z.; Kuritzkes, D. R.; Hughes, M.; Flexner, C.;
Gross, R.; Coakley, E.; Greaves, W.; Godfrey, C.; Skolnick, P. R.;
Timpone, J.; Rodriquez, B.; Gulick, R. M. HIV type-1 chemokine
co-receptor use among antiretroviral-experienced patients
screened for a clinical trial of a CCR5 antagonist: AIDS Clinical
trial group A5211. Clin. Infect. Dis. 2007, 44, 591–595.
(4) Waters, L.; Mandalia, S.; Randell, P.; Wildfire, A.; Gazzard, B.;
Moyle, G. The impact of HIV tropism on decreases in CD4 cell
count, clinical progression and subsequent response to a first
antiretroviral therapy regimen. Clin. Infect. Dis. 2008, 46, 1617–
1623.
(5) Goetz, M. B.; Leduc, R.; Kostman, J. R.; Labriola, A. M.; Lie, Y.;
Weidler, J.; Coakley, E.; Bates, M.; Luskin-Hawk, R. Relationship
between HIV coreceptor tropism and disease progression in per-
sons with untreated chronic HIV infection. JAIDS, J. Acquired
Immune Defic. Syndr. 2009, 50, 259–266.
(6) Hendrix, C. W.; Flexner, C.; MacFarland, R. T.; Giandomenico,
C.; Fuchs, E. J.; Redpath, E.; Bridger, G. J.; Henson, G. W.
Pharmacokinetics and Safety of AMD3100, a Novel Antagonist
of the CXCR4 Chemokine Receptor, in Human Volunteers. Anti-
microb.l Agents Chemother. 2000, 44, 1667–1673.
(7) Hendrix, C. W.; Collier, A. C.; Lederman, M. M.; Schols, D.;
Pollard, R. B.; Brown, S.; Jackson, J. B.; Coombs, R. W.; Glesby,
M. J.; Flexner, C. W.; Bridger, G. J.; Badel, K.; MacFarland, R. T.;
Henson, G. W.; Calandra, G. AMD3100 HIV Study Group.
Safety, pharmacokinetics, and antiviral activity of AMD3100, a
selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquired
Immune Defic. Syndr. 2004, 37, 1253–1262.
(8) Fransen, S.; Bridger, G.; Whitcomb, J. M.; Toma, J.; Stawiski, E.;
Parkin, N.; Petropoulos, C. J.; Huang, W. Suppression of dual-
tropic HIV-1 by the CXCR4 inhibitor AMD3100 is associated with
efficiency of CXCR4 use and baseline virus composition.
Antimicrob. Agents Chemother. 2008, 52, 2608–2615.
(9) Stone, N. D.; Dunaway, S. B.; Flexner, C.; Tierney, C.; Calandra,
G. B.; Becker, S.; Cao, Y. J.; Wiggins, I. P.; Conley, J.; MacFar-
land, R. T.; Park, J. G.; Llama, C.; Snyder, S.; Kallungal, B.;
Klingman, K. L.; Hendrix, C. W. Multiple-dose escalation study of
the safety, pharmacokinetics, and biologic activity of oral
AMD070, a selective CXCR4 receptor inhibitor, in human sub-
jects. Antimicrob. Agents Chemother. 2007, 51, 2351–2358.
(10) Moyle, G.; DeJesus, E.; Boffito, M.; Wong, R. S.; Gibney, C.;
Badel, K.; MacFarland, R.; Calandra, G.; Bridger, G.; Becker, S.
Proof of activity with AMD11070, an orally bioavailable inhibitor
of CXCR4-tropic HIV type 1. Clin. Infect. Dis. 2009, 48, 798–805.
(11) Crawford, J. B.; Chen, G.; Gauthier, D.; Wilson, T.; Carpenter, B.;
Baird, I. R.; McEachern, E.; Kaller, A.; Harwig, C.; Atsma, B.;
Skerlj, R. T.; Bridger, G. J. AMD070, a CXCR4 Chemokine
Receptor Antagonist: Practical Large-Scale Laboratory Synthesis.
Org. Process Res. Dev. 2008, 12, 823–830.
€
Fruehauf, S.; Horwitz, M.; Cooper, D.; Bridger, G.; Calandra,
G. Plerixafor and G-CSF versus Placebo and G-CSF to Mobilize
Hematopoietic Stem Cells for Autologous Stem Cell Transplanta-
tion in Patients with Multiple Myeloma. Blood 2009, 113, 5720–
5726.
(23) DiPersio, J. F.; Micallef, I. N.; Stiff, P. J.; Bolwell, B. J.; Maziarz,
R. T.; Jacobsen, E.; Nademanee, A.; McCarty, J.; Bridger, G.;
Calandra, G. Phase 3 Prospective Randomized Double Blind
Placebo-Controlled Trial of Plerixafor (AMD3100) plus Granulo-
cyte Colony-Stimulating Factor Versus Placebo plus Granulocyte
Colony-Stimulating Factor for Autologous Stem Cell Mobiliza-
tion and Transplantation in Patients with Non-Hodgkin’s
Lymphoma. J. Clin. Oncol. 2009, 27, 4767–4773.
(24) Micallef, I.; Stiff, P. J.; DiPersio, J. F.; Maziarz, R. T.; McCarty,
J. M.; Bridger, G.; Calandra, G. Successful Stem Cell Remobiliza-
tion by Plerixafor (Mozobil) plus Granulocyte Colony-Stimulating
Factor in Patients with Non-Hodgkin’s Lymphoma (NHL):
Results from the Plerixafor NHL Phase 3 Study Rescue Protocol.
Biol. Blood Marrow Transplant 2009, 15, 1578–1586.
(25) Calandra, G.; McCarty, J.; McGuirk, J.; Tricot, G.; Crocker, S. A.;
Badel, K.; Grove, B.; Dye, A.; Bridger, G. AMD3100 plus G-CSF
can successfully mobilize CD34þ cells from non-Hodgkin0s lym-
phoma, Hodgkin’s disease and multiple myeloma patients pre-
viously failing mobilization with chemotherapy and/or cytokine
treatment: compassionate use data. Bone Marrow Transplant 2008,
41, 331–338.
(26) Bridger, G. J.; Skerlj, R. T.; Thornton, D.; Padmanabhan, S.;
Martellucci, S. A.; et al. Synthesis and structure-activity relation-
ships of phenylenebis(methylene)-linked bis-tetraazamacrocycles
that inhibit HIV replication. Effects of macrocyclic ring size and
substituents on the aromatic linker. J. Med. Chem. 1995, 38, 366–
378.
(27) Bridger, G. J.; Skerlj, R. T.; Padmanabhan, S.; Martellucci, S. A.;
Henson, G. W.; et al. Synthesis and structure-activity relation-
ships of phenylenebis(methylene)-linked bis-tetraazamacrocycles
that inhibit human immunodeficiency virus replication. 2. Effect of
heteroaromatic linkers on the activity of bicyclams. J. Med. Chem.
1996, 39, 109–119.
(28) Bridger, G. J.; Skerlj, R. T.; Padmanabhan, S.; Martellucci, S. A.;
Henson, G. W.; et al. Synthesis and structure-activity relation-
ships of phenylenebis(methylene)-linked bis-azamacrocycles that
inhibit HIV-1 and HIV-2 replication by antagonism of the chemo-
kine receptor CXCR4. J. Med. Chem. 1999, 42, 3971–3981.
(29) Bridger, G.; Skerlj, R. T. Bicyclam derivatives as HIV inhibitors.
Adv. Antiviral Drug Des. 1999, 3, 161–229.
€
(12) Fatkenheuer, G.; Pozniak, A. L.; Johnson, M. A.; Plettenberg, A.;
Staszewski, S.; Hoepelman, A. I.; Saag, M. S.; Goebel, F. D.;
Rockstroh, J. K.; Dezube, B. J.; Jenkins, T. M.; Medhurst, C.;
Sullivan, J. F.; Ridgway, C.; Abel, S.; James, I. T.; Youle, M.; van
der Ryst, E. Efficacy of short-term monotherapy with maraviroc, a
new CCR5 antagonist, in patients infected with HIV-1. Nat. Med.
2005, 11, 1170–1172.
(13) Gulick, R. M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.;
Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.;
Montana, J. B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead,
S.; Dunne, M. W.; van der Ryst, E.; Mayer, H. Maraviroc for
previously treated patients with R5 HIV-1 infection. N. Engl. J.
Med. 2008, 359, 1429–1441.
(14) Baggiolini, M. Chemokines and Leukocyte Traffic. Nature 1998,
392, 565–568.
(15) Sallusto, F.; Baggiolini, M. Chemokines and Leukocyte Traffic.
(30) Gerlach, L. O.; Skerlj, R. T.; Bridger, G. J.; Schwartz, T. W.
Molecular Interactions of Cyclam and Bicyclam Non-peptide
Antagonists with the CXCR4 Chemokine Receptor. J. Biol. Chem.
2001, 276, 14153–14160.
Nature Immunol. 2008, 9, 949–952.